[CAS NO. 13292-46-1] Rifampicin

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [13292-46-1]

Catalog

HY-B0272

Brand

MCE

CAS

13292-46-1

DESCRIPTION [13292-46-1]

Overview

MDL	-
Molecular Weight	822.94
Molecular Formula	C43H58N4O12
SMILES	OC(C(/C=N/N1CCN(C)CC1)=C(NC(/C(C)=C\C=C\[C@@H]([C@@H]([C@@H](C)[C@H]2O)O)C)=O)C(O)=C3C(O)=C4C)=C3C5=C4O[C@](C)(O/C=C/[C@@H]([C@H]([C@@]([C@@H]2C)([H])OC(C)=O)C)OC)C5=O

For research use only. We do not sell to patients.

14 Publications Citing Use of MCE

Summary

Rifampicin is a potent and broad spectrum antibiotic against bacterial pathogens. Rifampicin has anti- influenza virus activities. Rifampicin shows anti-orthopoxvirus activity.

In Vitro

Rifampicin (100 mg/mL) can block the functional activity of P-glycoprotein. Rifampicin is not a substract for P-glycoprotein. The mechanism of rifampicin resistance is unassociated with the functional activity of P-glycoprotein ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Rifampicin (200, 400 mg/kg) can induce fatty liver at high concentration ^[1] . Rifampicin (30 mg/kg, i.p.) treatment of S464P biofilms in vivo results in a slight decline, but earlier rebinds in bioluminescence from these catheters compared with the parental signal, whereas rifampicin has no affect on bioluminescence in mice infected with mutant H481Y ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02581527	St George´s, University of London\|London School of Hygiene and Tropical Medicine\|University of Botswana	Pulmonary Tuberculosis	February 1, 2017	Phase 3
NCT03151499	Boehringer Ingelheim	Healthy	May 30, 2017	Phase 1
NCT01396265	Boehringer Ingelheim	Healthy	July 2011	Phase 1
NCT00004689	National Jewish Health\|FDA Office of Orphan Products Development	Mycobacterium Avium-intracellulare Infection	January 1991	Phase 2
NCT04493931	GlaxoSmithKline	Infections, Bacterial	August 14, 2020	Phase 1
NCT01757236	University Hospital, Tours\|Pfizer\|International Clinical Trials Association	Hip Prosthetic Joint Infection	October 2012	Phase 2
NCT00128206	University of California, San Francisco\|National Institute of Allergy and Infectious Diseases (NIAID)	Tuberculosis	November 2004	Phase 3
NCT04135833	Beta Pharma, Inc.	NSCLC	December 12, 2019	Phase 1
NCT01218217	Michael Hoelscher\|Sequella, Inc.\|European and Developing Countries Clinical Trials Partnership (EDCTP)\|German Federal Ministry of Education and Research\|Quintiles, Inc.\|CMed Technologies Inc.\|PathCare\|Parexel\|Ludwig-Maximilians - University of Munich	Tuberculosis, Pulmonary	November 2010	Phase 2
NCT01204112	Pfizer	Healthy	September 2010	Phase 1
NCT04266509	Pfizer	Healthy Volunteers	June 25, 2020	Phase 1
NCT03236987	Centre Hospitalier Universitaire, Amiens	Lung Infection\|Mycobacterium Avium Complex	February 5, 2018	Phase 3
NCT04029584	University of California, San Francisco	Drug-drug Interaction	April 25, 2019	Phase 4
NCT01910311	Eli Lilly and Company	Healthy Volunteers	August 2013	Phase 1
NCT03750721	Hospices Civils de Lyon	Bone and Joint Infection\|Antibiotic Resistant Staphylococcus Aureus Infection	April 1, 2018
NCT00620438	Makerere University\|Health Research Board, Ireland	HIV Infections\|Tuberculosis	February 2008	Phase 4
NCT05454345	First Affiliated Hospital of Zhejiang University	Tuberculosis, Pulmonary	October 1, 2022	Phase 3
NCT02253420	Bayer	Medical Oncology	October 8, 2014	Phase 1
NCT00000950	National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections\|Tuberculosis		Not Applicable
NCT01395927	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Healthy	July 2011	Phase 1
NCT01940510	Hoffmann-La Roche	Healthy Volunteer	October 2013	Phase 1
NCT01063270	Henry Ford Health System	Hidradenitis Suppurativa	February 2010	Not Applicable
NCT00304811	Michael E. DeBakey VA Medical Center\|Baylor College of Medicine	Staphylococcus Aureus	January 2006	Phase 4
NCT04537715	Epizyme, Inc.	All Malignancies\|Advanced Malignancies\|Hematologic Malignancy\|Solid Tumor\|Follicular Lymphoma (FL)\|Non-Hodgkin Lymphoma (NHL)\|Diffuse Large B-Cell Lymphoma (DLBCL)\|Epithelioid Sarcoma (ES)\|Synovial Sarcoma\|Renal Medullary Carcinoma\|Mesothelioma\|Rhabdoid Tumor	April 23, 2020	Phase 1
NCT01760642	Seoul National University Hospital	Healthy	December 2012	Phase 1
NCT02820935	Celgene Corporation	Pharmacokinetics	July 2016	Phase 1
NCT03709355	Viriom	HIV-1-infection	November 14, 2018	Phase 1
NCT01311505	Pfizer	Tuberculosis	April 2011	Phase 1
NCT02477852	Beijing Chest Hospital\|Beijing Municipal Science & Technology Commission	Tuberculosis, Spinal	April 2015	Phase 4
NCT01854489	Turku University Hospital	Healthy	April 2013	Phase 4
NCT01969682	AbbVie\|Genentech, Inc.	Non-Hodgkin´s Lymphoma	April 2014	Phase 1
NCT02875223	Celgene	Lymphoma, Non-Hodgkin\|Neoplasms	August 31, 2016	Phase 1
NCT03346837	Bristol-Myers Squibb	Malignancies Multiple	November 22, 2017	Phase 1
NCT01950364	Millennium Pharmaceuticals, Inc.	Hodgkin Lymphoma\|Anaplastic Large-cell Lymphoma	November 2013	Phase 1
NCT00864383	Global Alliance for TB Drug Development\|European and Developing Countries Clinical Trials Partnership (EDCTP)\|University College, London\|Bayer Healthcare Pharmaceuticals, Inc.+Bayer Schering Pharma\|Sanofi	Pulmonary Tuberculosis	January 2008	Phase 3
NCT01026415	Seagen Inc.\|Millennium Pharmaceuticals, Inc.	Carcinomas\|Disease, Hodgkin\|Lymphoma, Large-Cell, Anaplastic\|Lymphoma, Non-Hodgkin\|Neoplasms	December 2009	Phase 1
NCT03082183	Boehringer Ingelheim	Healthy	March 28, 2017	Phase 1
NCT04525235	Radboud University Medical Center	Tuberculosis	January 7, 2021	Phase 1
NCT04933682	Alexion Pharmaceuticals	Healthy	June 23, 2021	Phase 1
NCT02661893	Janssen Research & Development, LLC	Healthy	January 2016	Phase 1
NCT01324323	Celgene	Hematologic Malignancy\|Malignant Lymphoma	April 1, 2011	Phase 1
NCT01392911	Radboud University Medical Center\|European and Developing Countries Clinical Trials Partnership (EDCTP)\|Department of Clinical Pharmacy, University Medical Centre St Radboud, The Netherlands.\|University Centre for Chronic Diseases Dekkerswald, Groesbeek, NL	Pulmonary Tuberculosis (TB)	June 2011	Phase 2
NCT00935363	University of California, San Francisco	Healthy	February 2010	Phase 1
NCT05389722	Bristol-Myers Squibb	Healthy Volunteers	June 9, 2022	Phase 1
NCT02197247	AstraZeneca	Non Small Cell Lung Cancer	December 4, 2014	Phase 1
NCT02901288	Beijing Chest Hospital\|Hubei Provincial Center for Disease Control and Prevention\|Centre for Tuberculosis Control of Guangdong Province\|Hunan Institute For Tuberculosis Control\|Anhui Chest Hospital\|Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control\|Wuhan Institute for Tuberculosis Control\|Shanghai Pulmonary Hospital, Shanghai, China\|Shenyang Chest Hospital\|Changchun Infectious Disease Hospital\|First Affiliated Hospital of Xinjiang Medical University\|Public Health Clinical Center of Chengdu\|Taiyuan Fourth People´s Hospital\|The Sixth People´s Hospital of Nantong\|The Tuberculosis Prevention and Treatment Hospital of Shanxi Province\|Beijing Research Institute for Tuberculosis Control\|Infectious Disease Prevention Hospital in Heilongjiang Province\|The Third People´s Hospital of Zhenjiang\|Tianjin centers for Disease Control and Prevention\|Harbin Chest Hospital\|Chest of Hospital of Xinjiang Uygur Autonomous Region of the PRC\|Heilongjiang Province center for tuberculosis Control and Prevention\|Tianjin Haihe Hospital\|The Infectious Disease Hospital of Wangkai Zaozhuang\|The Third People´s Hospital of Kunming City\|Kaifeng Central Hospital\|The Infectious Hospital of Hebi\|Pulmonary Hospital of Lanzhou\|The Fourth People´s Hospital of Ningxia Autonomous Region\|The 4th People´s Hospital of Qinghai Province\|The Fifth People´s Hospital of Suzhou\|Chongqing Infectious Disease Medical Center\|Tuberculosis Hospital in Jilin Province\|Sixth People´s Hospital of Nanyang City\|Wuhan Union Hospital, China	Tuberculosis, Pulmonary	August 2016	Phase 4
NCT03012529	VA Office of Research and Development	Osteomyelitis\|Diabetes\|Amputation	January 22, 2018	Phase 4
NCT05021731	Miguel Santín\|Institut d´Investigació Biomèdica de Bellvitge\|Instituto de Salud Carlos III\|Hospital Universitari de Bellvitge	Latent Tuberculosis\|Kidney Failure	April 1, 2022	Phase 4
NCT05575297	Seoul National University Hospital	Drug Interaction	December 20, 2021	Phase 1
NCT00351273	University of South Florida\|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Arthritis, Reactive\|Reiter Disease	May 2006	Phase 3
NCT02055703	Eisai Inc.	Healthy Subjects	January 2014	Phase 1
NCT03278483	Instituto Nacional de Salud Publica, Mexico\|Instituto Nacional de Enfermedades Respiratorias\|Instituto Nacional de Ciencias Medicas y Nutrición	Diabetes Mellitus\|Tuberculin (Skin Test) Positive	February 28, 2019	Phase 4
NCT02393586	National University Hospital, Singapore	Tuberculosis	February 2015	Phase 1
NCT03077607	Pfizer\|Medivation, Inc.	Advanced Solid Tumors	November 7, 2016	Phase 1
NCT02602509	National University Hospital, Singapore	Tuberculosis	November 2015	Phase 1
NCT03586726	Hoffmann-La Roche	Healthy Volunteers	July 24, 2018	Phase 1
NCT05602597	Hutchmed	HMPL-689 Drug Interaction Study	June 1, 2022	Phase 1
NCT02959060	Bristol-Myers Squibb	Thrombosis	November 2016	Phase 1
NCT01408914	Harvard University Faculty of Medicine\|National Institute of Allergy and Infectious Diseases (NIAID)\|Sanofi\|Harvard School of Public Health (HSPH)\|Brigham and Women´s Hospital\|University of Liverpool\|St George´s, University of London\|University of Florida\|Socios en Salud	Tuberculosis	September 2013	Phase 2
NCT00776516	Astellas Pharma Inc	Pharmacokinetics of YM178	October 2008	Phase 1
NCT01251835	Pfizer	Pulmonary Arterial Hypertension	December 2010	Phase 1
NCT04437836	Kilimanjaro Clinical Research Institute\|European and Developing Countries Clinical Trials Partnership (EDCTP)	Clinical Trial	July 1, 2019	Phase 1\|Phase 2
NCT04121078	Millennium Pharmaceuticals, Inc.\|Takeda	Healthy Volunteers	October 15, 2019	Phase 1
NCT03782662	ReViral Ltd	Respiratory Syncytial Virus Infections	November 6, 2018	Phase 1
NCT02807116	CTI BioPharma\|Covance	Healthy Subjects	January 2015	Phase 1
NCT00207090	R-Pharm	Advanced Solid Tumors\|Neoplasms	September 2005	Phase 1
NCT00000641	National Institute of Allergy and Infectious Diseases (NIAID)	Mycobacterium Avium-intracellulare Infection\|HIV Infections		Phase 2
NCT02046850	AstraZeneca	Solid Tumours	February 2014	Phase 1
NCT03002493	Eisai Limited\|Eisai Inc.	Tumor	December 2009	Phase 1
NCT02500667	Nivalis Therapeutics, Inc.\|Davita Clinical Research	Drug Interaction Potentiation	June 2015	Phase 1
NCT03213145	Enanta Pharmaceuticals, Inc	NASH - Nonalcoholic Steatohepatitis	July 11, 2017	Phase 1
NCT00495326	French National Agency for Research on AIDS and Viral Hepatitis\|Medecins Sans Frontieres, Netherlands	Tuberculosis\|Aids\|Hiv Infections	December 2007	Phase 2\|Phase 3
NCT01929603	AstraZeneca	Solid Tumours	December 2013	Phase 1
NCT04504851	National University Hospital, Singapore	Pulmonary Tuberculosis	August 12, 2020	Phase 2
NCT01287221	Phillip Low\|National Institute of Neurological Disorders and Stroke (NINDS)\|Vanderbilt University\|Rare Disease Research Network Autonomic Consortium\|Mayo Clinic	Multiple System Atrophy	March 2011	Phase 3
NCT04951713	Xuanzhu Biopharmaceutical Co., Ltd.	Healthy	July 2021	Phase 1
NCT00715858	McMaster University\|The Physicians´ Services Incorporated Foundation	Alzheimer´s Disease	May 2008	Phase 3
NCT00985270	University of Oulu	Glucose Tolerance	September 2009	Phase 4
NCT03814200	Idorsia Pharmaceuticals Ltd.	Healthy Subject	January 3, 2019	Phase 1
NCT02836821	Jiangsu HengRui Medicine Co., Ltd.	Neoplasms	May 2016	Phase 1
NCT05497674	Sunshine Lake Pharma Co., Ltd.	Type 2 Diabetes Mellitus	February 21, 2022	Phase 1
NCT00000796	National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections\|Tuberculosis		Not Applicable
NCT03672630	Kevin Winthrop\|Patient-Centered Outcomes Research Institute\|National Jewish Health\|The University of Texas Health Science Center at Tyler\|University Health Network, Toronto\|New York University\|Medical University of South Carolina\|Mayo Clinic\|Louisiana State University Health Sciences Center in New Orleans\|University of California, San Diego\|Stanford University\|University of Kansas\|Vancouver Clinic\|University of California, San Francisco\|University of Washington\|Johns Hopkins University\|University of Miami\|Emory University\|University of Iowa\|University of North Carolina\|Temple University\|Loma Linda University\|Columbia University\|University of Wisconsin, Madison\|Northwell Health\|Oregon Health and Science University	Mycobacterium Avium Complex\|Nontuberculous Mycobacterium Infection	February 22, 2019	Phase 2\|Phase 3
NCT01231542	ViiV Healthcare\|Shionogi\|GlaxoSmithKline	Infection, Human Immunodeficiency Virus	May 2011	Phase 1
NCT01908582	Eli Lilly and Company	Healthy Volunteers	July 2013	Phase 1
NCT00741169	Tibotec Pharmaceuticals, Ireland	Hepatitis C\|HCV\|Tuberculosis\|Rifampin\|Pharmacokinetics	June 2008	Phase 1
NCT02085967	Eisai Inc.	Healthy Subjects	February 2014	Phase 1
NCT01561963	Amgen	Healthy Subjects	February 1, 2012	Phase 1
NCT00814671	Johns Hopkins University\|University of Cape Town Lung Institute\|University of Cape Town	Tuberculosis	April 2010	Phase 2
NCT03474198	University College, London\|National University Hospital, Singapore\|Singapore Clinical Research Institute (SCRI)	Tuberculosis, Pulmonary	March 21, 2018	Phase 2\|Phase 3
NCT04558216	Phathom Pharmaceuticals, Inc.	Healthy Participants	September 30, 2020	Phase 1
NCT05388448	TASK Applied Science\|GlaxoSmithKline\|European and Developing Countries Clinical Trials Partnership (EDCTP)	Tuberculosis, Pulmonary	April 21, 2022	Phase 2
NCT03622918	Gangnam Severance Hospital	Colistin\|Rifampin\|Acinetobacter Infections	October 27, 2016	Not Applicable
NCT04521803	University of Cape Town	Tuberculous Pericarditis\|HIV Status	January 6, 2022	Phase 2
NCT04312282	Odonate Therapeutics, Inc.	Advanced Solid Tumors	March 6, 2020	Phase 1
NCT02256267	Eli Lilly and Company	Healthy Volunteers	October 2014	Phase 1
NCT02729467	Janssen Research & Development, LLC	Healthy	March 2016	Phase 1
NCT00317330	National Institute of Allergy and Infectious Diseases (NIAID)	Tuberculosis	December 2004	Phase 3
NCT02563327	Centers for Disease Control and Prevention\|AIDS Clinical Trials Group	Tuberculosis	May 30, 2016	Phase 3
NCT02576366	Universitaire Ziekenhuizen KU Leuven	Drug Interactions\|Kidney Transplantation	June 2016	Phase 4
NCT00964106	GlaxoSmithKline	Drug Interactions	August 26, 2009	Phase 1
NCT00402454	Sociedad Andaluza de Enfermedades Infecciosas	HIV Infections	January 1994	Phase 4
NCT03301181	BeiGene	Healthy Volunteers: Asian, Non-Asian	September 18, 2017	Phase 1
NCT02024555	Vanderbilt University\|National Heart, Lung, and Blood Institute (NHLBI)\|Vanderbilt University Medical Center	Sarcoidosis; Antimycobacterial Therapy	March 2014	Phase 2
NCT02975440	Bayer	Endometriosis	November 10, 2016	Phase 1
NCT00777855	University of California, San Francisco	Healthy	November 2008	Not Applicable
NCT02804399	Pfizer	Healthy	July 2016	Phase 1
NCT02106767	University of California, San Francisco	Healthy	November 2014	Phase 1
NCT03991312	Agios Pharmaceuticals, Inc.	Healthy Volunteers	June 20, 2019	Phase 1
NCT01845298	Drexel University	HIV Infection	June 2014	Not Applicable
NCT02256696	Johns Hopkins University\|University of Cape Town	Pulmonary Tuberculosis	April 29, 2015	Phase 2
NCT05134337	Loxo Oncology, Inc.\|Eli Lilly and Company	Healthy Volunteers	February 12, 2020	Phase 1
NCT01679639	Hoffmann-La Roche	Healthy Volunteer	August 2012	Phase 1
NCT03353857	Bayer	Biological Availability	November 29, 2017	Phase 1
NCT01953731	Pfizer	Healthy	October 2013	Phase 1
NCT02770222	Actelion	Healthy Subjects	June 2016	Phase 1
NCT01293422	University of Oulu	Glucose Metabolism	January 2011	Phase 4
NCT01162486	Johns Hopkins University\|Sanofi\|Centers for Disease Control and Prevention	Tuberculosis\|Tuberculosis, Pulmonary	April 2010	Phase 1
NCT03301038	Children´s Hospital of Philadelphia\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Idiopathic Infantile Hypercalcaemia - Severe Form\|Genetic Disease\|Hypercalcemia, Idiopathic, of Infancy\|Hypercalciuric Hypercalcemia\|Idiopathic Infantile Hypercalcemia - Mild Form\|Hypercalciuria	July 25, 2018	Phase 2
NCT02701608	University Hospital, Tours	Infective Endocarditis	February 29, 2016	Phase 3
NCT00816426	National Institute of Allergy and Infectious Diseases (NIAID)\|Korean Center for Disease Control and Prevention\|International Tuberculosis Research Center\|Novartis Institute for Tropical Medicine\|Asian Medical Center\|National Institutes of Health Clinical Center (CC)	Tuberculosis	December 29, 2008	Phase 1
NCT01594827	Johns Hopkins University\|Case Western Reserve University\|Cystic Fibrosis Foundation	Cystic Fibrosis	October 2012	Phase 2
NCT00877591	University of California, San Francisco\|State University of New York at Buffalo\|University of Utah	Opioid Dependency\|HIV Infections	April 2008	Phase 1
NCT03624959	Celgene	Healthy Volunteer	June 20, 2018	Phase 1
NCT04070495	Kyowa Kirin Co., Ltd.	Parkinson´s Disease	August 27, 2019	Phase 1
NCT04672525	Tourcoing Hospital	Prosthetic Infection	November 8, 2021	Phase 3
NCT05069870	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Healthy Subjects	June 7, 2021	Phase 1
NCT01516203	National Institute of Allergy and Infectious Diseases (NIAID)	Tuberculosis	December 5, 2012	Phase 2
NCT05098041	Takeda	Healthy Volunteers	November 22, 2021	Phase 1
NCT05383742	National Institute of Allergy and Infectious Diseases (NIAID)	Tuberculous Meningitis	October 14, 2022	Phase 2
NCT03927313	University of Cape Town	Tuberculosis Meningitis\|HIV-1-infection	June 12, 2019	Phase 2
NCT00405080	GlaxoSmithKline	Nausea and Vomiting, Chemotherapy-Induced	November 11, 2006	Phase 1
NCT03063580	Sanofi	Diabetes Mellitus	February 27, 2017	Phase 1
NCT01424826	Helen Reynolds\|Liverpool University Hospitals NHS Foundation Trust\|University of Liverpool	HIV\|Tuberculosis	January 2012	Phase 1
NCT01844583	Millennium Pharmaceuticals, Inc.\|Takeda	Solid Tumors\|Lymphoma	June 25, 2013	Phase 1
NCT02387242	National University Hospital, Singapore	Tuberculosis	February 2015	Phase 1
NCT00170209	McGill University\|Canadian Institutes of Health Research (CIHR)	Latent Tuberculosis Infection	August 2011	Phase 3
NCT03723395	Seagen Inc.	Drug-drug Interaction	September 17, 2018	Phase 1
NCT01571414	National Institute of Allergy and Infectious Diseases (NIAID)	Tuberculosis	May 2012	Phase 1
NCT01323465	Jazz Pharmaceuticals	Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4\|Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4\|Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor	February 2008	Phase 1
NCT00000636	National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections\|Tuberculosis		Not Applicable
NCT04830462	Herlev and Gentofte Hospital	Latent Tuberculosis\|Diabetes Mellitus, Type 2	April 15, 2021	Phase 4
NCT00000638	National Institute of Allergy and Infectious Diseases (NIAID)\|Hoechst Marion Roussel\|Lederle Laboratories	HIV Infections\|Tuberculosis		Not Applicable
NCT03048110	Bayer\|Orion Corporation, Orion Pharma	Biological Availability	February 15, 2017	Phase 1
NCT05431673	Assiut University	Rhinoscleroma	August 21, 2022	Phase 1
NCT01386593	University Hospital, Basel, Switzerland	Metabolic Detoxication, Phase I	May 2011	Phase 1
NCT00931736	McGill University\|Canadian Institutes of Health Research (CIHR)	Latent Tuberculosis Infection	August 2009	Phase 3
NCT00001033	National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections\|Tuberculosis		Phase 3
NCT01068756	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes Mellitus	March 2010	Phase 1
NCT03758469	Sichuan Haisco Pharmaceutical Group Co., Ltd\|Haisco Pharmaceutical Group Co., Ltd.	Anesthesia\|Sedation	December 14, 2018	Phase 1
NCT05577624	Amgen	Healthy Participants	November 5, 2019	Phase 1
NCT02216331	Global Alliance for TB Drug Development	Tuberculosis	March 2010	Phase 1
NCT04565574	Eisai Co., Ltd.\|Eisai Inc.	Healthy Participants	October 16, 2020	Phase 1
NCT01426906	LG Life Sciences	Healthy Male Volunteers	January 2011	Phase 1
NCT04187469	Fifth Affiliated Hospital, Sun Yat-Sen University	Pulmonary Tuberculosis	March 1, 2020	Not Applicable
NCT03478033	Shanghai Public Health Clinical Center\|The Guangxi Zhuang Autonomous Region Longtan hospital\|The Fourth People´s Hospital of Nanning\|Shenzhen Third People´s Hospital\|Yunnan Provincial Infectious Disease Hospital\|Zhejiang University\|Chongqing Public Health Medical Center	Tuberculosis, Pulmonary\|AIDS	April 15, 2018	Not Applicable
NCT02381470	National University Hospital, Singapore	Pulmonary Tuberculosis	February 11, 2019	Phase 2
NCT05597280	Institute of Tropical Medicine, Belgium	Leprosy	March 1, 2023	Phase 3
NCT01763021	Janssen Research & Development, LLC	Healthy Participants	December 2012	Phase 1
NCT04268394	Celgene	Healthy Volunteer	March 13, 2020	Phase 1
NCT03486314	Millennium Pharmaceuticals, Inc.\|Takeda	Advanced Solid Neoplasm	August 13, 2018	Phase 1
NCT02507167	University Medicine Greifswald	Gastrointestinal Hormones	November 2012	Phase 1
NCT02957448	Bristol-Myers Squibb	Atherothrombotic Diseases	November 2016	Phase 1
NCT00367913	British Thoracic Society	Pulmonary Diseases	March 1995	Phase 4
NCT01388075	Hadassah Medical Organization	Healthy Subjects	July 2011	Not Applicable
NCT04768231	Hospital Universitari Vall d´Hebron Research Institute\|University Medical Center Groningen\|Radboud University Medical Center\|Centro Hospitalar De São João, E.P.E.\|Instituto Nacional de Enfermedades Respiratorias y del Ambiente, Paraguay	Tuberculosis	April 1, 2021	Phase 2
NCT01765543	Hoffmann-La Roche	Malignant Melanoma, Neoplasms	July 2013	Phase 1
NCT01398618	National Taiwan University Hospital	Latent Tuberculosis Infection	May 2011	Phase 3
NCT04011124	Jiangsu HengRui Medicine Co., Ltd.	Healthy Male Subjects	July 24, 2019	Phase 1
NCT04577885	Jiangsu HengRui Medicine Co., Ltd.	Healthy	May 28, 2020	Phase 1
NCT00669643	University of Brasilia\|Conselho Nacional de Desenvolvimento Científico e Tecnológico\|Ministry of Science and Technology, Brazil\|Ministry of Health, Brazil\|Fundação Alfredo da Matta, Manaus, Brazil\|Instituto de Dermatologia Dona Libania, Fortaleza, Brazil	Leprosy	February 2007	Phase 4
NCT05398679	Fundacion Clinic per a la Recerca Biomédica	Endocarditis Infective	June 1, 2022	Phase 4
NCT01690104	University of Oulu\|Oulu University Hospital	Blood Pressure Regulation	August 2012	Phase 4
NCT04301310	Bristol-Myers Squibb	Healthy Participants	March 9, 2020	Phase 1
NCT00534807	Bristol-Myers Squibb	Cancer	September 2007	Phase 1
NCT01401933	Abbott	Advanced Solid Tumors	May 2011	Phase 1
NCT03199690	St. Stephens Clinical Research\|St Stephens Aids Trust	HIV-1-infection\|Tuberculosis	October 2017	Phase 1
NCT04410094	Janssen Research & Development, LLC	Healthy	September 14, 2020	Phase 1
NCT01601626	AIDS Clinical Trials Group\|National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infection\|Tuberculosis	July 13, 2013	Phase 2
NCT01591850	Hoffmann-La Roche	Healthy Volunteer	September 2011	Phase 1
NCT04311502	National Institute of Allergy and Infectious Diseases (NIAID)	HIV\|Tuberculosis	June 16, 2021	Phase 2
NCT01637636	Vanda Pharmaceuticals	Healthy	June 2012	Phase 1
NCT04630145	Janssen Pharmaceutical K.K.	Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)	January 8, 2021	Phase 2\|Phase 3
NCT04166669	Pfizer	Fungal Infection	November 12, 2019	Phase 1
NCT03983239	Celgene\|Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation	Healthy Volunteers	June 21, 2019	Phase 1
NCT03994211	BeiGene	Solid Tumor	June 19, 2019	Phase 1
NCT01169038	Vanderbilt University	Pulmonary Sarcoidosis\|Lung Function	July 2010	Phase 1
NCT02457208	University of Oxford	Tuberculosis	July 7, 2015	Phase 1
NCT01770392	Boehringer Ingelheim	Healthy	January 2013	Phase 1
NCT01785186	Michael Hoelscher\|Sequella, Inc.\|European and Developing Countries Clinical Trials Partnership (EDCTP)\|German Federal Ministry of Education and Research\|Medical Research Council\|Radboud University Medical Center\|Ludwig-Maximilians - University of Munich	Tuberculosis, Pulmonary	April 2013	Phase 2
NCT03326050	Assiut University	Rhinoscleroma	February 2018	Early Phase 1
NCT03712540	Bristol-Myers Squibb	Healthy Participants	September 6, 2018	Phase 1
NCT01589497	AIDS Clinical Trials Group\|National Institute of Allergy and Infectious Diseases (NIAID)	Tuberculosis	June 30, 2015	Phase 2
NCT01322438	Bayer	Neoplasms	March 2011	Phase 1
NCT04150367	Yuria-Pharm	Tuberculosis, Pulmonary	March 3, 2017
NCT04485156	Seoul National University Hospital\|Chonnam National University Hospital\|National Medical Center, Seoul\|Pusan National University Hospital\|Pusan National University Yangsan Hospital\|Seoul National University Bundang Hospital\|SMG-SNU Boramae Medical Center\|Severance Hospital\|Korean Institute of Tuberculosis\|International Tuberculosis Research Center\|Korean Center for Disease Control and Prevention	Tuberculosis, Pulmonary	September 2020	Phase 3
NCT01441206	University of North Carolina, Chapel Hill\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Infection	September 2011	Phase 1
NCT04951986	University of Cape Town	Disseminated Tuberculosis\|HIV	August 11, 2021	Phase 3
NCT01018368	Vertex Pharmaceuticals Incorporated	Cystic Fibrosis	November 2009	Phase 1
NCT04808648	Nanjing Sanhome Pharmaceutical, Co., Ltd.	Healthy Male Volunteers	April 6, 2021	Phase 1
NCT05156437	Vinay Badhwar\|West Virginia University	Endocarditis	March 16, 2022	Phase 4
NCT00439166	Hamilton Health Sciences Corporation\|The Physicians´ Services Incorporated Foundation\|McMaster University	Alzheimer´s Disease	February 2007	Phase 3
NCT01147055	Pfizer	Healthy	July 2010	Phase 1
NCT02706535	GlaxoSmithKline	Drug Interactions\|Neoplasms	May 5, 2016	Phase 1
NCT00096850	National Institute of Allergy and Infectious Diseases (NIAID)\|AIDS Clinical Trials Group	HIV Infections\|Tuberculosis		Not Applicable
NCT01576575	Washington University School of Medicine	Healthy	June 2010	Not Applicable
NCT03755778	Enanta Pharmaceuticals, Inc\|Pharmaceutical Research Associates	RSV Infection	November 29, 2018	Phase 1
NCT01655147	Janssen Research & Development, LLC	Healthy	January 2012	Phase 1
NCT02138799	Astellas Pharma Europe B.V.\|Medivation, Inc.\|Astellas Pharma Inc	Drug-Drug Interaction (DDI)\|Healthy Subjects\|Pharmacokinetics of Enzalutamide	July 2013	Phase 1
NCT02782078	Assistance Publique - Hôpitaux de Paris	Staphylococcal Infections	March 6, 2017	Not Applicable
NCT05556746	Brigham and Women´s Hospital\|University of Cape Town\|Haitian Group for the Study of Kaposi´s Sarcoma and Opportunistic\|University of Stellenbosch\|University of California, Los Angeles\|Harvard School of Public Health (HSPH)	Tuberculosis, Pulmonary\|HIV	March 2023	Phase 2
NCT04290390	TherapeuticsMD	Women\|Contraception	February 12, 2020	Phase 1
NCT04060719	Boehringer Ingelheim	Healthy	September 4, 2019	Phase 1
NCT00384280	Wyeth is now a wholly owned subsidiary of Pfizer	Healthy	September 2006	Phase 1
NCT01002079	Bristol-Myers Squibb\|PRA Health Sciences	Alzheimer Disease	August 2010	Phase 1
NCT00694629	Centers for Disease Control and Prevention\|Sanofi	Pulmonary Tuberculosis	December 2008	Phase 2
NCT05047055	Tuberculosis Research Centre, India\|Indira Gandhi Govt. Medical College and Hospital (IGGMCH), Nagpur\|King George´s Medical University, Lucknow\|Mahavir Hospital and Research Centre, Hyderabad\|Govt. Vellore Medical College and Hospital, Adukkamparai\|Lok Nayak hospital, New Delhi	Tuberculosis, Pulmonary	October 1, 2021
NCT01577862	University of Campania Luigi Vanvitelli\|Federico II University	Infection Due to Resistant Bacteria\|Pneumonia, Ventilator-Associated\|Hospital Acquired Pneumonia\|Infection of Bloodstream\|Infectious Disease of Abdomen	November 2008	Phase 3
NCT01634100	Boehringer Ingelheim	Healthy	June 2012	Phase 1
NCT03384121	The Hospital for Sick Children\|Children´s Hospital of Philadelphia\|Canadian Institutes of Health Research (CIHR)\|Cures Within Reach	Idiopathic Infantile Hypercalcemia - Mild Form	February 22, 2018	Phase 1
NCT01340456	Karolinska University Hospital\|AstraZeneca	CYP3A4 Induction	May 2011	Not Applicable
NCT01406002	Astellas Pharma Inc	Pharmacokinetics of Darexaban and Metabolites\|Healthy Subjects	January 2010	Phase 1
NCT01533870	AstraZeneca	Drug Induced Constipation	March 2012	Phase 1
NCT05316857	Beijing InnoCare Pharma Tech Co., Ltd.	Healthy Person	December 16, 2021	Phase 1
NCT05357820	AnHeart Therapeutics Inc.	Solid Tumor	July 19, 2021	Phase 1
NCT02174250	Kyowa Hakko Kirin Pharma, Inc.\|Kyowa Kirin, Inc.	Parkinson´s Disease	June 2014	Phase 1
NCT04930744	University of Massachusetts, Worcester\|National Institute of Allergy and Infectious Diseases (NIAID)\|Aurum Institute\|A*STAR Infectious Diseases Labs\|University of Cape Town	Tuberculosis\|Pulmonary Tuberculosis\|HIV Coinfection	August 3, 2021	Phase 2
NCT01500837	Assistance Publique - Hôpitaux de Paris	Osteoarticular Infection	October 2010	Not Applicable
NCT04439578	Jiangsu HengRui Medicine Co., Ltd.	Healthy Subjects	June 23, 2020	Phase 1
NCT02372383	University of Colorado, Denver\|Cystic Fibrosis Foundation\|Colorado Clinical & Translational Sciences Institute	Cystic Fibrosis	October 2014	Not Applicable
NCT02554318	University of Giessen\|Indonesian Directorate General of Higher Education	Pulmonary Tuberculosis\|Body Weight Changes\|Motor Activity	November 2013	Not Applicable
NCT04142762	Assembly Biosciences	Chronic Hepatitis B	October 18, 2019	Phase 1
NCT02019875	University of Washington	Vitamin D and Calcium Homeostasis	June 2014	Not Applicable
NCT02329405	University of Oulu\|Oulu University Hospital	Non-alcoholic Fatty Liver Disease	December 2014	Phase 4
NCT04649723	Jiangsu HengRui Medicine Co., Ltd.	Healthy Subjects, Drug-drug Interaction, Pharmacokinetics, SHR1459	November 24, 2020	Phase 1
NCT04118842	AstraZeneca	Solid Tumors	October 17, 2019	Phase 1
NCT00182429	McMaster University\|The Physicians´ Services Incorporated Foundation	Clostridium Enterocolitis\|Antibiotic-Associated Diarrhea\|Pseudomembranous Colitis\|Pseudomembranous Enterocolitis\|Pseudomembranous Enteritis	February 2004	Phase 3
NCT03116893	Boehringer Ingelheim	Healthy	April 19, 2017	Phase 1
NCT01043575	Centers for Disease Control and Prevention	Smear Positive, Pan-sensitive, Pulmonary Tuberculosis	April 2009	Phase 2
NCT05169554	Fundacion Agencia Aragonesa para la Investigacion y Desarrollo (ARAID)\|Universidad de Zaragoza\|Fondation Raoul Follereau\|Université d´Abomey-Calavi\|Instituto de Salud Carlos III\|Fundación Anesvad	Buruli Ulcer	December 1, 2021	Phase 2
NCT01447511	University of Minnesota\|National Institute of General Medical Sciences (NIGMS)	Healthy	May 2009	Not Applicable
NCT00608907	Millennium Pharmaceuticals, Inc.\|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Multiple Myeloma\|Non-Hodgkin´s Lymphoma	September 2007	Phase 1
NCT02097953	University of Utah\|Cubist Pharmaceuticals LLC	Drug Interactions\|Pharmacokinetics	May 2014	Early Phase 1
NCT00419172	Novartis	Healthy	January 2007	Phase 1
NCT02286635	PTC Therapeutics	Healthy Volunteers	November 2014	Phase 1
NCT05338489	Eli Lilly and Company\|Loxo Oncology, Inc.	Healthy	May 11, 2018	Phase 1
NCT02547116	Johns Hopkins University	Cystic Fibrosis\|MRSA	December 2020	Phase 4
NCT04557397	Hutchison Medipharma Limited\|Covance\|Hutchmed	Drug Drug Interaction	September 2, 2020	Phase 1
NCT01349192	University of North Carolina, Chapel Hill\|CF Therapeutics Development Network Coordinating Center\|Seattle Children´s Hospital\|Washington University School of Medicine\|University of Washington\|University of Colorado, Denver\|Baylor College of Medicine\|University of Alabama at Birmingham\|Cook Children´s Medical Center\|University of Michigan\|University of Florida\|University of Texas Southwestern Medical Center\|Children´s Hospital Medical Center, Cincinnati\|St. Louis Children´s Hospital	Cystic Fibrosis\|Methicillin-resistant Staphylococcus Aureus	April 2011	Phase 2
NCT05372367	Boehringer Ingelheim	Solid Tumors	June 30, 2022	Phase 1
NCT01947777	SecuraBio	Healthy	October 2013	Phase 1
NCT01438515	Horizon Health Network	Methicillin-resistant Staphylococcus Aureus	August 2008	Not Applicable
NCT02809768	Eisai Inc.	Healthy Participants	April 2016	Phase 1
NCT00043264	National Center for Research Resources (NCRR)\|National Multiple Sclerosis Society	Multiple Sclerosis		Phase 2
NCT03982277	Makerere University	Tuberculosis	April 30, 2019	Phase 2
NCT04532918	AstraZeneca\|Parexel	Chronic Kidney Disease	September 10, 2020	Phase 1
NCT01336218	AstraZeneca	Rheumatoid Arthritis\|Healthy Volunteers	April 2011	Phase 1
NCT02183584	Boehringer Ingelheim	Healthy	September 2009	Phase 1
NCT04843449	Ascletis Pharmaceuticals Co., Ltd.	Healthy	April 4, 2021	Phase 1
NCT05359055	Shanghai Pharmaceuticals Holding Co., Ltd	Drug Drug Interaction	December 13, 2021	Phase 1\|Phase 2
NCT00402610	Sociedad Andaluza de Enfermedades Infecciosas	HIV Infections\|Tuberculosis	January 1994	Phase 4
NCT01802502	Universitas Padjadjaran\|Radboud University Medical Center	Tuberculous Meningitis	June 2013	Phase 2
NCT03596294	Idorsia Pharmaceuticals Ltd.	Healthy Subjects	July 19, 2018	Phase 1
NCT03173053	Radboud University Medical Center\|ZonMw: The Netherlands Organisation for Health Research and Development\|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)\|University College, London	Staphylococcus Aureus\|Motility Disorder	February 8, 2018	Not Applicable
NCT05057949	Sunshine Lake Pharma Co., Ltd.	Healthy Volunteers	November 24, 2021	Phase 1
NCT03928327	Millennium Pharmaceuticals, Inc.\|Takeda	Healthy Volunteers	May 2, 2019	Phase 1
NCT05255276	Mirati Therapeutics Inc.	Healthy Adults	January 29, 2022	Phase 1
NCT05268120	Leiden University Medical Center	MRSA	July 25, 2022	Not Applicable
NCT01454076	Millennium Pharmaceuticals, Inc.\|Takeda	Nonhematologic Malignancies\|Lymphoma	November 10, 2011	Phase 1
NCT03340662	Celgene	Healthy Volunteer	November 9, 2017	Phase 1
NCT00760149	Radboud University Medical Center\|European and Developing Countries Clinical Trials Partnership (EDCTP)\|Sanofi\|Kilimanjaro Christian Medical Centre, Tanzania\|Kibong´oto National Tuberculosis Hospital, Sanya Juu, Tanzania\|University Centre for Chronic Diseases Dekkerswald, Groesbeek, The Netherlands\|National Institute for Public Health and the Environment (RIVM)	Tuberculosis	July 2010	Phase 2
NCT03307252	Boehringer Ingelheim	Healthy	October 25, 2017	Phase 1
NCT00023374	Centers for Disease Control and Prevention\|US Department of Veterans Affairs	Tuberculosis	August 2000	Not Applicable
NCT03174184	Johns Hopkins University	Tuberculosis, Pulmonary	August 23, 2017	Phase 2
NCT03892161	University of Cape Town\|Wits Reproductive Health and HIV Institute\|Desmond Tutu HIV Centre	HIV Infections	April 12, 2018	Phase 1
NCT03988933	McGill University Health Centre+Research Institute of the McGill University Health Centre\|Canadian Institutes of Health Research (CIHR)	Latent Tuberculosis	September 20, 2019	Phase 2
NCT00057122	National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections\|Tuberculosis	September 2002	Phase 3
NCT00226538	Hadassah Medical Organization	Healthy Volunteers	August 1999	Not Applicable
NCT01756924	Arrevus Inc.	Prosthetic Joint Infections of Hip\|Prosthetic Joint Infections of Knee\|Infected Spacers	December 2012	Phase 2
NCT00585195	Pfizer	Non-Small Cell Lung Cancer ALK-positive\|Non-Small Cell Lung Cancer c-Met Dependent\|Non-Small Cell Lung Cancer ROS Marker Positive\|Systemic Anaplastic Large-Cell Lymphoma\|Advanced Malignancies Except Leukemia	April 19, 2006	Phase 1
NCT04606537	KBP Biosciences\|Covance	Healthy\|Drug Drug Interaction	October 24, 2020	Phase 1
NCT00405301	All India Institute of Medical Sciences, New Delhi	Drug Induced Hepatotoxicity\|Tuberculosis	December 2006	Phase 4
NCT01341184	National Institute of Allergy and Infectious Diseases (NIAID)	Tuberculosis	October 21, 2011	Phase 1
NCT00568711	Dong-Min Kim\|Chosun University Hospital	Scrub Typhus	September 2006	Not Applicable
NCT03662022	Institute of Tropical Medicine, Belgium\|Damien Foundation\|Centre d´Infectiologie Charles Mérieux\|Fondation Raoul Follereau\|Leiden University Medical Center\|L´Institut National de la Santé et de la Recherche Médicale\|Genoscreen\|Instituto Fernandes Figueira	Leprosy	January 2, 2019	Phase 3
NCT00906048	Sanofi	Infection	April 2009	Phase 3
NCT03530995	Kadmon Corporation, LLC\|Quotient Sciences	Drug-drug Interaction\|Autoimmune Diseases\|Fibrotic Disease	April 9, 2018	Phase 1
NCT04959266	AstraZeneca\|Parexel	Advanced Solid Tumours	June 28, 2021	Phase 1
NCT03801746	Akebia Therapeutics	Drug Interaction Potentiation	July 20, 2018	Phase 1
NCT04914936	Acerta Pharma BV	Healthy Participants	September 21, 2014	Phase 1
NCT02275962	Kowa Research Institute, Inc.	Healthy	September 2014	Phase 1
NCT00621309	University of Washington\|Fred Hutchinson Cancer Center\|National Institute of General Medical Sciences (NIGMS)	Adverse Drug Interactions	March 2008	Phase 1
NCT00042289	National Institute of Allergy and Infectious Diseases (NIAID)\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	HIV Infections	June 9, 2003
NCT02430545	Pfizer	Healthy Volunteers	May 2015	Phase 1
NCT03474029	Centers for Disease Control and Prevention\|British Medical Research Council	Latent Tuberculosis	August 1, 2019	Phase 2\|Phase 3
NCT00696566	Sheffield Teaching Hospitals NHS Foundation Trust\|British Heart Foundation\|University of Sheffield	Coronary Artery Disease	November 2007	Phase 1
NCT01154959	Tuberculosis Research Centre, India\|National Institutes of Health (NIH)	Pulmonary Tuberculosis	February 2010	Phase 3
NCT01026714	University Hospital, Geneva	Healthy Volunteers	November 2009	Phase 1\|Phase 2
NCT01814709	Genentech, Inc.	Healthy Volunteer	April 2013	Phase 1
NCT03563950	Bristol-Myers Squibb	Healthy Participants	June 1, 2018	Phase 1
NCT01768663	Vertex Pharmaceuticals Incorporated	Cystic Fibrosis	January 2013	Phase 1
NCT02328443	Seoul National University Hospital	Healthy	January 2014	Phase 1
NCT01218620	National Cancer Institute (NCI)	Adult Solid Neoplasm	September 2010	Phase 1
NCT03311841	Merck Sharp & Dohme LLC	Renal Insufficiency	March 1, 2018	Phase 1
NCT02846519	Janssen Research & Development, LLC	Healthy	February 26, 2016	Phase 1
NCT04494659	Jiangsu HengRui Medicine Co., Ltd.	Healthy Adult Subjects	July 20, 2020	Phase 1
NCT04921943	Oregon Health and Science University\|NTM Info & Research, Inc.\|University Health Network, Toronto\|New York University	Nontuberculous Mycobacterial Lung Disease\|Nontuberculous Mycobacterium Infection	May 18, 2021	Phase 4
NCT00130247	National Institute of Allergy and Infectious Diseases (NIAID)	Tuberculosis	April 8, 2002	Phase 3
NCT02608034	Genentech, Inc.	Metastatic Melanoma, BRAF V600 Mutation Positive	May 26, 2016	Phase 1
NCT02173717	Boehringer Ingelheim	Healthy	June 2009	Phase 1
NCT02409004	PTC Therapeutics	Healthy	February 2015	Phase 1
NCT05069688	Brigham and Women´s Hospital\|APIN Public Health Initiatives\|University of Cape Town	Pediatric HIV Infection\|Tuberculosis Infection	January 1, 2022	Phase 1
NCT01121133	AbbVie	Lymphoma, Including Chronic Lymphocytic Leukemia\|Solid Tumors	May 2010	Phase 1
NCT04463680	University of Colorado, Denver\|Merck Sharp & Dohme LLC	Contraception\|Tuberculosis	September 23, 2020	Phase 4
NCT00127504	Centers for Disease Control and Prevention\|Universidad del Valle, Guatemala\|University of Alabama at Birmingham	Onchocerciasis	July 2003	Phase 2
NCT02169882	Universitas Padjadjaran\|United States Agency for International Development (USAID)\|Radboud University Medical Center	Tuberculosis, Meningeal	December 1, 2014	Phase 2\|Phase 3
NCT03637790	Pfizer	Healthy	September 13, 2018	Phase 1
NCT03186482	St. Stephens Clinical Research\|St Stephens Aids Trust	HIV	June 1, 2017	Phase 1
NCT02599493	Rennes University Hospital	Osteoarticular Infection	January 2016	Phase 4
NCT01954043	GlaxoSmithKline	Cancer	December 20, 2013	Phase 1
NCT00711854	University Hospital, Geneva	MRSA Infection	January 2009	Phase 4
NCT04171739	F2G Biotech GmbH\|Hammersmith Medicines Research	Healthy	November 18, 2019	Phase 1
NCT04694586	University Hospital, Linkoeping\|Linkoeping University	Tuberculosis, Pulmonary	November 23, 2020	Phase 2
NCT02440841	Vantia Ltd	Nocturia	May 2015	Phase 1
NCT00938262	Boryung Pharmaceutical Co., Ltd	Essential Hypertension	April 2009	Phase 1
NCT03296800	Theracos	Type 2 Diabetes Mellitus	September 27, 2017	Phase 1
NCT05586568	Xuanzhu Biopharmaceutical Co., Ltd.	Healthy Subjects	November 15, 2022	Phase 1
NCT01297855	Mahidol University	Drug Safety	June 2010	Phase 3
NCT01932268	Seoul National University Hospital	Chronic Kidney Disease\|Tuberculosis	January 2011	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL ( 30.38 mM ; ultrasonic and warming and heat to 80°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.2152 mL	6.0758 mL	12.1516 mL
5 mM	0.2430 mL	1.2152 mL	2.4303 mL
10 mM	0.1215 mL	0.6076 mL	1.2152 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: 2.5 mg/mL (3.04 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (3.04 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

Rifamycin, 3-[[(4-methyl-1-piperazinyl)imino]methyl]-

2,7-(Epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan-1,11(2H)-dione, 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-, 21-acetate

2,7-(Epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan-1,11(2H)-dione, 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,20,22-heptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-, 21-acetate

2,7-(Epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan, rifamycin deriv.

3-[[(4-Methyl-1-piperazinyl)imino]methyl]rifamycin

5,6,9,17,19,21-Hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-2,7-(epoxypentadeca[1,11,13]trienimino)-naphtho[2,1-b]furan-1,11(2H)-dione 21-acetate

Rifampicin

Rifampin

Rifaldazine

Rifamycin AMP

Rimactan

Rifampicin SV

Rifadin

3-[(4-Methyl-1-piperazinyl)iminomethyl]rifamycin SV

R/AMP

Rifa

Rifadine

Rifaldin

Rifoldine

Riforal

Tubocin

NSC 113926

Sinerdol

Famcin

R-Cin

Rimapen

NIH 10782

Rifaprodin

Eremfat

Refampicin

Ba 41166/E

Rimactane

Abrifam

Rifoldin

L 5103 Lepetit

Rifacap

Rifodex

Rifactine